Based on IDH mutations along with the 1p/19q codeletion, tumor protein 53 (TP53) mutation, ATP-dependent X-linked helicase (ATRX) mutation, and telomerase reverse transcriptase (TERT) promoters mutation, gliomas can be classified into different groups with distinct pathogenesis and prognosis [1, 8, 9]. The gene discussed is IDH2; the disease is central nervous system cancer.